Crown Castle Files Investor Presentation Highlighting Clear Strategic Plan and Refreshed, Experienced Board to Drive Shareholder Value Creation The Company’s Board, alongside newly appointed CEO Steven Moskowitz, is taking action to improve performance, unlock value within the fiber and small cell business, and create a stronger and more valuable Crown Castle Ted Miller’s demands to take de facto control of the Company, along with three of his friends and family, put shareholders’ investment in Crown Castle at risk Shareholders urged to vote the WHITE proxy card or voting instruction form...
Perspective Therapeutics to Participate at Upcoming May Investor Conferences SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) -- (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in the following upcoming investor conferences as scheduled below, and will be available for one-on-one meetings with investors. Guggenheim Healthcare Talks | Radiopharmaceuticals DayDate: Monday, May 13, 2024Location: Ne...
ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The committed capital will be available to Novocure in four tranches of $100 million. The first $100 million was issued at closing, and the second $100 million will be issued by June 30, 2025. An additional $200 million is available to be drawn across two tranches, at Novocure’s discretion and subject to certain milestones, through March 31, 2026. The proceeds will be used ...
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its first quarter 2024 financial results and provide a business update on Wednesday, May 15, 2024 before market open. The press release will be available on the newsroom section of the Company’s website at . About Perspective Therapeutics, Inc.Perspective Therapeu...
ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “The first quarter was a period of strong execution,” said William Doyle, Novocure’s Executive Chairman. “In Q1, GBM active patients grew 11%, we announced the METIS Phase 3 clinical trial met its primary endpoint, and we met with the U.S. Food and Drug Administ...
Universal Stainless Reports Near-Record Sales and Profitability in First Quarter of 2024 Q1 2024 Sales of $77.6 million vs. record $79.8 million in Q4 2023; up 18% from Q1 2023Q1 2024 Gross Margin reaches 18.9% of sales, highest since Q1 2012, despite $1.3 million raw material headwindQ1 2024 Net Income up 59% from Q4 2023 to $4.1 million, or $0.43 per diluted share Cash flow from operations totals $10.3 million, up 39% from Q4 2023 Backlog increases to $325 million on strong order entry BRIDGEVILLE, Pa., May 01, 2024 (GLOBE NEWSWIRE) -- Universal Stainless & Alloy Products, Inc. (Nasda...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.